Innovative Infection Control Vomaris leverages proprietary bioelectric technology to combat a broad spectrum of microbes and prevent biofilm formation, making its products highly relevant for hospitals, clinics, and wound care centers seeking advanced infection management solutions.

Growing Product Portfolio The recent launch of OTC bioelectric bandages and flexible wound dressings demonstrates product expansion and responsiveness to market needs, creating opportunities for sales into outpatient clinics, dermatology, and emergency care providers.

Strategic Collaborations Partnerships with institutions like the University of Miami indicate a focus on clinical validation, which can be leveraged to build credibility and accelerate adoption in medical institutions and research-focused healthcare providers.

Funding and Revenue Growth With $8 million in funding and current revenues between $1 million and $10 million, Vomaris is positioned for growth, making it an attractive partner for medical distributors and healthcare organizations seeking innovative wound care technologies.

Expansion Opportunities The focus on expanding applications to PPE and other infection control products opens avenues to sell across various healthcare supply chains, including outpatient, long-term care, and institutional markets looking for sustainable, high-efficacy solutions.